Eligible patients must be ≥18 years old, have adequate organ function, and meet disease-specific criteria (NSCLC: EGFR-mutant, prior 3rd-gen TKI; BC: HR+/HER2-, prior CDK4/6i + endocrine therapy). Key exclusions include prior HER3-targeted therapy, uncontrolled cardiovascular/ocular disease, active infections, severe toxicities, or unresolved organ dysfunction. Pregnancy, breastfeeding, or immunosuppressive conditions are also disqualifying.

YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle. The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes.

Eligible patients must be ≥18 years old, have adequate organ function, and meet disease-specific criteria (NSCLC: EGFR-mutant, prior 3rd-gen TKI; BC: HR+/HER2-, prior CDK4/6i + endocrine therapy). Key exclusions include prior HER3-targeted therapy, uncontrolled cardiovascular/ocular disease, active infections, severe toxicities, or unresolved organ dysfunction. Pregnancy, breastfeeding, or immunosuppressive conditions are also disqualifying.

YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle. The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes.

Eligible patients had advanced/metastatic HR-/HER2- or HR+/HER2-low breast cancer post-ADC failures, measurable lesions, adequate organ function, and life expectancy ≥3 months. Key exclusions included prior HER3 therapy, topoisomerase I inhibitor intolerance, active infections, uncontrolled comorbidities, recent major surgery/vaccines, CNS metastases, or other malignancies within 5 years.

Eligible patients (18-75 years) must have histologically confirmed advanced/metastatic solid tumors (e.g., NSCLC, BC, HNSCC), ≥1 measurable lesion, ECOG PS 0-1, adequate organ function, and contraception compliance. Exclusions involve prior HER3-targeted therapy, topoisomerase I inhibitor intolerance, recent major surgery/live vaccines, uncontrolled comorbidities (CNS metastases, cardiovascular/pulmonary/GI disorders, infections, HIV/HBV/HCV), other malignancies, or pregnancy/lactation.